

Melanoma Patients

Reference Number: F4870
Date of Response: 16/09/2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Royal Devon's Eastern FOI Office Response

Q1. In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with:

- Bevacizumab (Avastin) – **0 patients**
- Dacarbazine (DTIC) – **0 patients**
- Trametinib (Mekinist) – **0 patients**
- Dabrafenib (Tafinlar) – *** patients**
- Ipilimumab (Yervoy) – *** patients**
- Vemurafenib (Zelboraf) – **0 patients**
- Nivolumab (Opdivo) – **6 patients**
- Nivolumab + Ipilimumab (Opdivo + Yervoy) – **5 patients**
- Pembrolizumab (Keytruda) – **50 patients**
- Vemurafenib + cobimetinib (Zelboraf + Cotellic) – **0 patients**
- Dabrafenib + Trametinib (Tafinlar + Mekinist) – **9 patients**
- Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients – **0 patients**
- Other active systemic anti-cancer therapy [please state] – **8 patients (Other SACT: Talimogene laherparepvec, Bleomycin, Binimetinib, Encorafenib)**
- Palliative care only – **0 patients**

* - ≤5.

In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles.

Low number suppressed to protect patient identity.

Q2. In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following:

- Ipilimumab – * <5 patients
- Ipilimumab AND Nivolumab – * <5 patients
- Nivolumab – * <5 patients
- Pembrolizumab – 18 patients
- Dabrafenib AND Trametinib – 6 patients
- Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib) – 0 patients
- Other active systemic anti-cancer therapy – 6 patients
- Palliative care only – 0 patients

* - <5 Low number suppressed to protect patient identity.